Pan-cancer trials for therapies targeting BRAF mutations have included BTC patients: the ROAR trial testing dabrafenib plus trametinib in BRAF V600E-mutated cancers found promising results (n of BTC cases = 43 [31]), while the BEAVER trial found only modest clinical activity for binimetinib and encorafenib for non-V600E tumors (BTC n = 6 [32]). The gene discussed is BRAF; the disease is cancer.